- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02421328
Study of the Effects of CPAP and HHHFNC on Diaphragmatic Dimensions in Preterm Infants
Comparative Study of the Effects of Continuous Positive Airway Pressure and Heated, Humidified High Flow Nasal Cannula on Diaphragmatic Dimensions in Preterm Infants
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Preterm infants will be recruited consecutively from NICU of Mansoura University Children's Hospital. They will be randomized in two groups; one group will start on nasal CPAP (Fisher & Paykel Healthcare, Auckland, New Z ealand) (Pressure 5 cmH2O) for 60 minutes and then will be switched to HHHFNC (Fisher & Paykel Healthcare, Auckland, New Z ealand) (flow of 4 l/m) for another 60 minutes. The other group will start on HHHFNC and then switched to nasal CPAP.
After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be analyzed in different respiratory cycles and the average of 3 cycles will be calculated at the end of the 60 minutes periods on nasal CPAP and HHHFNC.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Dakahlia
-
Mansoura, Dakahlia, Egypten, 35516
- Neonatal Intensive Care Unit, Mansoura University Children Hospital
-
Mansoura, Dakahlia, Egypten, 35516
- NICU, Mansoura University Children's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Preterm infants < 37 weeks.
- Stable on nasal continuous positive airway pressure (CPAP) for at least 24 hours.
- On less than 35% oxygen.
Exclusion Criteria:
- Congenital and acquired problems of the gastrointestinal tract as necrotizing enterocolitis, esophageal perforation and tracheoesophageal fistula.
- Phrenic nerve injury and/or diaphragm paralysis
- Congenital/acquired neurological deficit and/or seizures
- Hemodynamic instability
- Congenital heart disease (including symptomatic patent ductus arteriosus)
- Undergoing treatment for sepsis or pneumonia.
- Use of muscle relaxants, narcotic analgesics, or gastric motility agents.
- Congenital anomalies of respiratory tract.
- Infants requiring more than 35% oxygen.
- Infants with facial anomalies.
- Infants with pneumothorax and/or pneumomediatinum.
- Infants in the immediate postoperative period.
- Infants with significant gastric residues and vomiting.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: CPAP first
Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC.
After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
|
Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
|
|
Aktiv komparator: HHHFNC first
Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP.
After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
|
Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diaphragmatic dimensions (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness)
Tidsramme: at the end of each 60 minutes epoch on nasal CPAP
|
Ultrasonographic assessment of (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness will be assessed at the end of each 60 minutes epoch on nasal CPAP.
Diaphragm thickness will be measured as the perpendicular distance between the pleural and peritoneal reflections.
All measurements will be performed during quiet breathing.
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minutes epoch on nasal CPAP
|
|
Right and left diaphragmatic excursion
Tidsramme: at the end of each 60 minute epoch on CPAP
|
Ultrasonographic assessment of right and left diaphragmatic excursion will be assessed at the end of each 60 minutes epoch on nasal CPAP.
The displacements of the liver and spleen will be monitored in real-time.
Using M-mode ultrasonography, with the probe fixed on the chest wall during respiration, ultrasonographic image of will be frozen and a mark for measurement will be placed on the image at the location of the most caudal margin of the liver or spleen at the end of expiration, and a second mark will be placed on the new location of the most caudal margin of the liver or spleen at the end of inspiration.
The distance between the two marks will be then measured and defined as the displacement of the liver or the spleen (right or left diaphragmatic excursion).
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minute epoch on CPAP
|
|
Diaphragmatic dimensions (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness)
Tidsramme: at the end of each 60 minutes epochs on HHHNC
|
Ultrasonographic assessment of (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness will be assessed at the end of each 60 minutes epoch on HHHFNC.
Diaphragm thickness will be measured as the perpendicular distance between the pleural and peritoneal reflections.
All measurements will be performed during quiet breathing.
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minutes epochs on HHHNC
|
|
Right and left diaphragmatic excursion
Tidsramme: at the end of each 60 minutes epochs on HHHNC
|
Ultrasonographic assessment of right and left diaphragmatic excursion will be assessed at the end of each 60 minutes epoch on HHHFNC.
The displacements of the liver and spleen will be monitored in real-time.
Using M-mode ultrasonography, with the probe fixed on the chest wall during respiration, ultrasonographic image of will be frozen and a mark for measurement will be placed on the image at the location of the most caudal margin of the liver or spleen at the end of expiration, and a second mark will be placed on the new location of the most caudal margin of the liver or spleen at the end of inspiration.
The distance between the two marks will be then measured and defined as the displacement of the liver or the spleen (right or left diaphragmatic excursion).
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minutes epochs on HHHNC
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Respiratory rate
Tidsramme: At the end of each 60 minutes epochs on CPAP and HHHFNC
|
Respiratory rate will be assessed at the end of each 60 minutes epoch on CPAP or HHHFNC
|
At the end of each 60 minutes epochs on CPAP and HHHFNC
|
|
Heart rate
Tidsramme: At the end of each 60 minutes epochs on CPAP and HHHFNC
|
Heart rate will be assessed at the end of each 60 minutes epoch on CPAP or HHHFNC
|
At the end of each 60 minutes epochs on CPAP and HHHFNC
|
|
Spo2
Tidsramme: At the end of each 60 minutes epochs on CPAP and HHHFNC
|
Oxygen saturation by pulse oximetry (SpO2) will be assessed at the end of each 60 minutes epoch on CPAP or HHHFNC
|
At the end of each 60 minutes epochs on CPAP and HHHFNC
|
|
Number of apneas
Tidsramme: during the 60 minutes epochs on CPAP and HHHFNC
|
Number of apneas will be recorded during the 60 minutes epoch on CPAP or HHHFNC
|
during the 60 minutes epochs on CPAP and HHHFNC
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- MS 874
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med CPAP first (Fisher & Paykel Healthcare)
-
Fisher and Paykel HealthcareAfsluttet
-
Fisher and Paykel HealthcareAfsluttet
-
Associação Fundo de Incentivo à PesquisaFisher and Paykel Healthcare; Philips RespironicsUkendt
-
All India Institute of Medical Sciences, New DelhiAfsluttet
-
Changi General HospitalAfsluttet
-
Johns Hopkins UniversityUniversity of North Carolina, Chapel Hill; Children's Hospital Medical... og andre samarbejdspartnereAfsluttetLungebetændelse | Fejlernæring | Hypoxæmi | Humant immundefektvirus (HIV)Malawi